Pure Global
NCT06263452

Beta-Blocker Influences on Inflammatory and Neural Responses to Stress

University of North Carolina, Chapel Hill·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cardiovascular Disease
Drug/Device/Intervention
Propranolol
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of North Carolina, Chapel Hill
Location
Chapel Hill, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Mar 01, 2024
End date
Mar 01, 2026
Enrollment
120 participants
Primary outcome

Change in levels of pro-inflammatory cytokine interleukin-6 in response to social stress,Change in levels of inflammatory gene expression in response to social stress

Summary

The purpose of this study is to map the neural and molecular mechanisms underlying
 psychological stress-induced changes in inflammation which could reveal new targets for
 intervention to reduce the risk of cardiovascular disease.

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseHeart disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06263452
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06263452 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of North Carolina, Chapel Hill and is currently Not yet recruiting. The study focuses on Cardiovascular Disease. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.